Pinned Tweet
Oncternal Therapeutics is a true #SanDiego innovation story! Founded, funded and run in San Diego. Learn more about our pipeline of drug candidates for cancer and rare malignancies oncternal.com
1
We presented interim data from the ongoing, investigator-sponsored Ph1b clinical study of our investigational product candidate, cirmtuzumab, at the @SABCSSanAntonio Breast Cancer Symposium. Check out our presentation and release on our website! #SABCS19 oncternal.peek.link/9Aq
3
We announced the enrollment opening for a Ph1b clinical trial expansion cohort of our investigational product candidate TK216 in Ewing sarcoma patients following favorable interim results & continuing our mission to develop novel therapies for #RareDisease https://teapaw.org/t.co/g3AsDwlqlk
Oncternal Therapeutics retweeted
The @ASH_hematology 2019 Meeting featured the promising results of four #CIRM funded clinical trials conducted by @FortySevenInc @SangamoTx @oncternal and Rocket Pharmaceuticals https://teapaw.org/t.co/vuAHDIrrCG
We are proud to have been part of the @ASH_hematology 2019 Meeting where a clinical data update was presented on our investigational product candidate cirmtuzumab in combination with ibrutinib. In case you missed us, learn more on our website! #ASH2019 oncternal.peek.link/9wQ
3
Oncternal Therapeutics retweeted
Honoring the living legend David Hale tonight as our 2019 Connect Hall of Fame inductee. Thank you for being a co-founder of Connect and a champion of entrepreneurship and San Diego! #InnovationAwards #ConnectSD
Congratulations to our Chairman David Hale on being inducted into the @CONNECTinSD Entrepreneur Hall of Fame at last night’s 2019 #InnovationAwards!
1
We are looking forward to attending the 31st Annual @PiperJaffrayCo Healthcare Conference this year! Check out our President and CEO Jim Breitmeyer presenting a company overview on Thursday, December 5 at 11:50 a.m. ET oncternal.peek.link/99o
1
We will be presenting at the @Stifel Healthcare Conference today at 4:10 p.m. ET. Check out the live webcast on our website here: oncternal.peek.link/96S
3
This week we presented interim clinical data from our Phase 1 trial of TK216 in Ewing Sarcoma at the @ctosociety 2019 Annual Meeting. We are encouraged by the early activity and look forward to continuing the momentum #CTOS2019 oncternal.peek.link/938
3
Dr. Hun Ju Lee, MD, spoke with @TargetedOnc about our Phase Ib clinical study of Cirmtuzumab in combination with ibrutinib, which now includes an expansion cohort in patients with mantle cell lymphoma. Check out the full interview here: https://teapaw.org/t.co/QcGWPKP8dm
We are proud to be able to share our innovative company story, diverse pipeline of potentially first-in-class product candidates and collaboration with @CIRMnews at the @SDInnovCouncil Meeting!
Proud to see #JLABSSD graduate @oncternal featured as a San Diego commercialization success story 🏆 at the @SDInnovCouncil Showcase!
2
We announced our Q3 financial results and provided an update on the opening of a Ph2 study of Cirmtuzumab in combination with ibrutinib in patients with CLL and a Ph1b expansion cohort in patients with MCL. Join us for a live webcast at 2:00 p.m. PT https://teapaw.org/t.co/RSm6NpWJwl
1
Our CEO Jim Breitmeyer spoke with the @wstranscript on his journey at Oncternal and our innovative pipeline of cancer product candidates. Read the feature here: https://teapaw.org/t.co/iIRuOSHfxj
1
Oncternal Therapeutics retweeted
Encouraging progress for two #cirm supported trials conducted by @Capricor and @oncternal #DuchenneMuscularDystrophy #lymphoma https://teapaw.org/t.co/OCdxfTVSdH
Oncternal Therapeutics retweeted
We’re excited to kick-off a new series on #PediatricCancer that highlights companies seeking novel therapies for children, a long-standing challenge.
Very thankful to @Oncternal CEO James Breitmeyer for sharing his thoughts with us. #InnovationThatMatters https://teapaw.org/t.co/bV8bW4wjxd
Today we announced an additional complete response in a MCL patient treated with cirmtuzumab + ibrutinib. We also opened enrollment of the Phase 1b expansion cohort of our MCL clinical trial. This follows our interim data at the @ASCO meeting in June! https://teapaw.org/t.co/PqJ0wFXmPL
1
In case you missed it: Nasdaq hosted Oncternal’s CEO Jim Breitmeyer on their San Diego #biotech edition of the Nasdaq Spotlight Series in July! Thank you @Nasdaq and @Ivonne_romeo #NasdaqSpotlight
✈We visit @Oncternal Therapeutics in its hometown of San Diego to hear about its story from the ground up and how it's developing first-in-class product candidates for cancers. #NasdaqSanDiego
Nasdaq San Diego: Oncternal
3
In honor of #WorldCancerResearchDay today, we would like to share our commitment in pioneering innovative areas of cancer research to create new treatments for patients with critical unmet medical needs!
1
This week, our President and CEO Jim Breitmeyer spoke with @WuXi_AppTec about our investigational product candidate in clinical trials to treat patients with Ewing Sarcoma and the challenging field of #pediatriccancer https://teapaw.org/t.co/CFSgtLk5b3
Dr. Paul Meyers and the pediatric oncology team at @sloan_kettering presented a case study of our investigational product candidate TK216 in a patient with Ewing Sarcoma at the Fall @COGorg Meeting. Read the announcement here: https://teapaw.org/t.co/Sffy2xSY0W











